Pravastatin prevents aortic atherosclerosis via modulation of signal transduction and activation of transcription 3 (STAT3) to attenuate interleukin-6 (IL-6) action in ApoE knockout mice

Int J Mol Sci. 2008 Nov;9(11):2253-2264. doi: 10.3390/ijms9112253. Epub 2008 Nov 14.

Abstract

The purpose of this study was to determine whether pravastatin's prevention of aortic atherosclerosis via attenuation of IL-6 action depends on modulation of STAT3 activity. Male apoE knockout (apoE-/-) mice fed on a diet containing 1.25% cholesterol (wt/wt) were divided into pravastatin group provided with pravastatin (80 mg kg(-1) per day) and atherosclerosis group. After eight weeks, pravastatin significantly prevented atherosclerotic lesion and reduced levels of IL-6 in serum and lesion, and significantly decreased expressions of phosphorylated STAT3 (pSTAT3) and increased suppressor of cytokine signaling 3 (SOCS3) expressions in lesions. Our results suggested that pravastatin's aortic atherosclerosis preventing action via attenuation of IL-6 action may partially depend on modulation of STAT3 activity.

Keywords: IL-6; Pravastatin; SOCS3; STAT3; atherosclerosis.